NeoThetis: Colorectal
Colorectal cancer is the third most common type of cancer worldwide. In 2020, nearly 2 million people were diagnosed with colorectal cancer, and it is estimated that by 2040 the new cases will increase to about 3.2 million. There are different risk factors, both environmental and hereditary, that can cause the development of colorectal cancer. These include lack of physical activity and family history. Somatic and hereditary germline mutations, such as mutations in the APC, BRAF, KRAS genes, and others, have been linked to colorectal cancer initiation and progression. This panel identifies the genetic mutations in 34 genes in the circulating tumour DNA, which can offer improved prognostic assessment, guide tailored therapies to each patient and help increase the chances of survival.
Microsatellite instability (MSI) immunotherapy biomarker has been linked to colorectal cancer. Indeed, many colorectal cancer patients display high MSI status, with studies linking high MSI status with good outcome and improved prognosis for patients with colorectal cancer. / immunotherapy treatments such as nivolumab and pembrolizumab are available for colorectal cancer patients with MSI-high status.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?
Certified laboratories
